IGFBP6 Antibody

What is IGFBP6 and why is it important in biological research?

IGFBP6 (Insulin-like Growth Factor Binding Protein 6) is an O-linked glycoprotein that preferentially binds IGF-II over IGF-I. It functions primarily as a selective inhibitor of IGF-II actions, including proliferation, survival, and differentiation in various cell types . Beyond its IGF-dependent roles, IGFBP6 exhibits numerous IGF-independent functions such as promoting apoptosis in certain cells and inhibiting angiogenesis .

IGFBP6 has emerged as an important research target due to its:

• Potential tumor-suppressive properties in several cancers

• Role in inducing migration of certain tumor cells via MAP kinase-mediated mechanisms

• Ability to enter the nucleus and modulate cell survival and differentiation

• Involvement in vascular inflammation and atherosclerosis

• Altered expression in various pathological conditions including cancer and cystic fibrosis

Research involving IGFBP6 antibodies is critical for understanding these diverse biological functions and their implications in disease pathogenesis.

What types of IGFBP6 antibodies are available for research applications?

Several types of IGFBP6 antibodies are available for research purposes:

• Monoclonal antibodies: Such as Mouse Anti-Human IGFBP-6 Monoclonal Antibody (Clone #164428) , which offers high specificity for targeted epitopes.

• Polyclonal antibodies: Including Goat Anti-Human IGFBP-6 Antigen Affinity-purified Polyclonal Antibody , which recognizes multiple epitopes on the IGFBP6 protein.

• Neutralizing antibodies: Antibodies capable of inhibiting IGFBP6 biological activity, as demonstrated in neutralization assays with recombinant IGFBP6 and IGF-II .

• Detection antibodies: Optimized for specific applications like ELISA, Western blotting, or immunohistochemistry .

When selecting an appropriate antibody, researchers should consider the specific application, required sensitivity, and whether functional (neutralizing) or purely detection capabilities are needed.

How can I validate the specificity of an IGFBP6 antibody for my research?

Thorough validation of IGFBP6 antibody specificity is essential for reliable research outcomes. A comprehensive validation approach includes:

• Western blot analysis: Verify the antibody detects a band of appropriate molecular weight (~25-30 kDa for IGFBP6). Compare with positive and negative control samples to confirm specificity .

• Antigen-antibody specificity testing: As demonstrated in IGF signaling antibody arrays, test the antibody with antigen mixtures at defined concentrations (e.g., 10 ng/ml) to confirm specific binding to IGFBP6 without cross-reactivity to other IGF family proteins .

• Coefficient of variation assessment: Evaluate reproducibility across multiple replicates, as demonstrated in antibody array development where variability was measured by comparing signals from replicated spots within the same array and across different arrays .

• Recombinant protein controls: Use recombinant IGFBP6 protein as a positive control in your assays, especially when establishing standard curves .

• Knock-down/knock-out validation: Where possible, use IGFBP6 knock-down/knock-out cell lines to confirm antibody specificity through disappearance of the target signal.

What are the primary research applications for IGFBP6 antibodies?

IGFBP6 antibodies serve multiple research applications:

• Protein detection and quantification:

  • Western blotting for expression analysis in cell/tissue lysates

  • ELISA for quantitative measurement of secreted IGFBP6 in culture media or biological fluids

  • Immunohistochemistry for localization in tissue samples

• Functional studies:

  • Neutralization experiments to block IGFBP6 activity and study resulting biological effects

  • Investigation of IGFBP6's role in cell proliferation, as demonstrated in MCF-7 breast cancer cell line studies

• Signaling pathway analysis:

  • Studying IGFBP6's interaction with the MVP-JNK/NF-κB signaling axis in inflammation contexts

  • Investigating IGF-dependent and IGF-independent functions

• Biomarker research:

  • Evaluating IGFBP6 expression in patient samples to assess its value as a prognostic biomarker in cancers like glioma and breast cancer

How can IGFBP6 antibodies be utilized to investigate IGF-dependent versus IGF-independent functions?

Distinguishing between IGF-dependent and IGF-independent functions of IGFBP6 requires strategic experimental design with IGFBP6 antibodies:

• For IGF-dependent mechanisms:

  • Perform neutralization assays using IGFBP6 antibodies in the presence of both IGFBP6 and IGF-II. The neutralization dose (ND50) of 5-25 µg/mL antibody typically reverses IGFBP6 (0.8 µg/mL) inhibition of IGF-II (14 ng/mL) in proliferation assays .

  • Include IGF-II competitive binding assays with and without IGFBP6 antibody to demonstrate specificity of the IGF-dependent pathway.

  • Use receptor blocking approaches (IGF-1R antibodies) in combination with IGFBP6 antibodies to delineate receptor-mediated effects.

• For IGF-independent mechanisms:

  • Design experiments in IGF-II knockout/knockdown systems where IGFBP6 antibody neutralization still shows biological effects.

  • Investigate IGFBP6's interaction with prohibitin-2 (a known binding partner mediating IGF-independent migration) using co-immunoprecipitation with IGFBP6 antibodies .

  • Employ IGFBP6 antibodies in subcellular localization studies to track nuclear translocation, which is associated with IGF-independent actions .

• Comparative approaches:

  • Use dose-response studies with recombinant IGFBP6 (0.2-200 ng/ml) with and without neutralizing antibodies while monitoring both IGF-dependent pathways (IGF receptor phosphorylation) and IGF-independent pathways (MAP kinases) .

The recent finding that IGFBP6 executes anti-inflammatory effects through the MVP-JNK/NF-κB signaling axis provides a useful model system for studying IGF-independent functions using antibody neutralization approaches.

What are the challenges in interpreting data from IGFBP6 expression studies in different disease models?

Researchers face several challenges when interpreting IGFBP6 expression data across disease models:

• Tissue-specific and context-dependent expression patterns:

  • IGFBP6 is significantly reduced in human atherosclerotic arteries and patient serum

  • IGFBP6 expression is significantly upregulated in glioblastoma compared to lower-grade gliomas

  • In cystic fibrosis, IGFBP6 expression is higher in F508del-CFTR cells than in wild-type CFTR cells

  • IGFBP6 is downregulated in primary and metastatic ovarian cancer tissues compared to normal ovarian tissues

• Dual roles in cancer progression:

  • While generally reported as downregulated in most cancers (suggesting tumor suppressor functions) , IGFBP6 is upregulated in specific tumors like glioblastoma

  • This apparent contradiction requires careful interpretation through molecular profiling and functional validation

• Influence of experimental conditions:

  • Inflammatory stimuli like LPS and cytokines (IL-1β/TNFα) can significantly increase IGFBP6 expression

  • Flow conditions (disturbed vs. laminar) affect IGFBP6 expression in vascular studies

• Methodology-related variables:

  • Detection sensitivity varies between antibody-based methods

  • Protein vs. mRNA expression discrepancies may occur

To address these challenges, researchers should:

• Employ multiple detection methods (qRT-PCR, Western blot, ELISA)

• Include appropriate disease and normal controls

• Consider the influence of experimental conditions on expression

• Validate findings with functional studies using neutralizing antibodies

How can IGFBP6 antibodies be employed in studying the role of IGFBP6 in cancer progression?

IGFBP6 antibodies can be strategically deployed to investigate IGFBP6's complex roles in cancer progression:

• Expression profiling across cancer stages:

  • Use antibody-based techniques (immunohistochemistry, Western blot) to analyze IGFBP6 expression patterns in tumor tissues versus adjacent normal tissues

  • Correlation with clinical parameters, as demonstrated in the breast cancer study where IGFBP6 expression was associated with type 2 diabetes status (Table 1 from source ):

• Functional neutralization studies:

  • Use neutralizing antibodies (like those described in sources and ) to block IGFBP6 function in cancer cell lines

  • Measure subsequent effects on:

    • Proliferation (as demonstrated in MCF-7 breast cancer cells)

    • Migration and invasion capabilities

    • Angiogenesis (IGFBP6 inhibits VEGF-induced angiogenesis)

    • Survival and apoptosis pathways

• Signaling pathway investigations:

  • Combine IGFBP6 antibody treatments with pathway inhibitors to delineate mechanisms

  • Analyze effects on IGF-dependent pathways (IGF-1R/IGF-2R activation)

  • Investigate IGF-independent pathways (MAP kinases, prohibitin-2 interactions)

• In vivo xenograft models:

  • Apply IGFBP6 antibodies in xenograft models to understand cancer progression in vivo

  • Previous research showed IGFBP6 inhibited growth of neuroblastoma and rhabdomyosarcoma xenografts

  • Antibody neutralization studies could further validate these findings

• Combination therapy approaches:

  • Test IGFBP6 antibodies in combination with established cancer therapies

  • Prior research showed additive effects between IGFBP6 overexpression and CCI-779 (rapamycin analogue) in delaying tumor formation

What considerations are important when developing multiplex assays that include IGFBP6 antibodies?

Developing robust multiplex assays incorporating IGFBP6 antibodies requires addressing several key considerations:

• Antibody compatibility and cross-reactivity:

  • Validate antibody specificity against all target proteins in the multiplex panel

  • In the IGF signaling antibody array, specificity testing showed minimal cross-reactivity between antibodies targeting ten different IGF family proteins (IGF-1, IGF-1R, IGF-2, IGF-2R, IGFBP-1, IGFBP-2, IGFBP-3, IGFBP-4, IGFBP-6, and Insulin)

  • Employ orthogonal validation methods to confirm specificity

• Optimizing detection sensitivity:

  • Develop standard curves for each target protein at appropriate concentration ranges

  • The IGF signaling antibody array achieved detection sensitivities in the pg/ml to ng/ml range, with minimal detected levels at 7.8 pg/ml

  • Balance antibody concentrations to achieve comparable sensitivity across all analytes

• Reproducibility and variability assessment:

  • Evaluate coefficient of variation across:

    • Replicated spots within the same array

    • Different arrays within the same slide

    • Separate arrays from different slides

  • Establish acceptance criteria for assay reliability

• Sample preparation considerations:

  • Standardize lysate preparation methods to ensure consistent protein extraction

  • Optimize blocking conditions to minimize background without affecting specific binding

  • Consider potential matrix effects in complex biological samples

• Data analysis and normalization:

  • Develop appropriate data extraction software, similar to the Genpix software used for IGF signaling array analysis

  • Establish data normalization methods to account for technical variability

  • Create standard curves with high correlation coefficients (R²>0.97) for quantitative measurements

• Validation with orthogonal methods:

  • Confirm multiplex results with single-plex methods like ELISA or Western blot

  • Validate biological findings with functional assays

What are the optimal conditions for using IGFBP6 antibodies in neutralization assays?

Effective neutralization assays with IGFBP6 antibodies require careful optimization of several experimental parameters:

• Antibody concentration determination:

  • Typical neutralization dose (ND50) ranges from 5-25 µg/mL for monoclonal antibodies and 8-24 µg/mL for polyclonal antibodies

  • Perform dose-response experiments to determine optimal antibody concentration for your specific system

• IGFBP6 and IGF-II concentrations:

  • Standard conditions use 0.8 µg/mL recombinant human IGFBP-6 and 14 ng/mL recombinant human IGF-II

  • These concentrations have been validated in MCF-7 human breast cancer cell proliferation assays

• Incubation conditions:

  • For cell-based assays, typical treatment duration is 24-48 hours to observe proliferation effects

  • For inflammatory response studies, shorter timeframes (4-24 hours) are often sufficient

• Controls and validation:

  • Include controls for:

    • Antibody alone (to assess direct antibody effects)

    • IGFBP6 alone (to confirm inhibitory activity)

    • IGF-II alone (to establish baseline stimulation)

  • Use dose-response curves to demonstrate specificity of neutralization

• Readout selection:

  • Cell proliferation can be measured via standard proliferation assays (MTT, BrdU)

  • For inflammatory studies, measure cytokine expression (IL-1β, IL-6, TNF-α) by qRT-PCR

  • ELISA can quantify secreted proteins in culture supernatants

• Cell type considerations:

  • MCF-7 breast cancer cells are well-established for IGF-II-dependent proliferation assays

  • F508del-CFTR CFBE cells have been validated for inflammatory response studies

How should I optimize IGFBP6 antibodies for Western blot analysis of tissues with variable expression levels?

Optimizing Western blot protocols for IGFBP6 detection across tissues with varying expression requires systematic approach:

• Sample preparation optimization:

  • Use lysis buffers with protease inhibitors to prevent IGFBP6 degradation

  • Consider tissue-specific extraction protocols to maximize protein yield

  • Normalize loading based on total protein rather than single housekeeping proteins

• Antibody selection and dilution:

  • For low-expressing tissues, polyclonal antibodies may provide higher sensitivity

  • Starting dilution ranges:

    • 1:500 for rabbit recombinant anti-IGFBP6 antibodies

    • 1:1000 for mouse monoclonal antibodies

  • Perform antibody titration to determine optimal concentration

• Detection system enhancement:

  • Employ high-sensitivity ECL systems like Clarity Max Western ECL for low abundance detection

  • Consider signal amplification systems for tissues with very low expression

  • Use digital imaging systems (e.g., ChemiDoc) with extended exposure capabilities

• Positive and negative controls:

  • Include recombinant IGFBP6 protein as positive control

  • Use tissues with known IGFBP6 expression profiles:

    • F508del-CFTR cells (higher IGFBP6 expression)

    • Non-CF cells (lower IGFBP6 expression)

• Quantification and normalization:

  • Use robust densitometry software like ImageJ

  • Normalize to appropriate loading controls (Calnexin has been validated)

  • Consider using ratio-based approaches (IGFBP6/Calnexin) for comparisons across tissues

• Troubleshooting strategies:

  • For weak signals: increase primary antibody concentration, extend incubation time, use signal enhancement systems

  • For high background: optimize blocking, increase washing stringency, decrease antibody concentration

  • For multiple bands: verify specificity with peptide competition assays

What are the best practices for developing quantitative ELISA assays for measuring IGFBP6 in biological samples?

Developing reliable quantitative ELISA assays for IGFBP6 requires careful consideration of several factors:

• Antibody pair selection:

  • Choose validated antibody pairs with demonstrated specificity for IGFBP6

  • Consider pre-validated commercial ELISA kits (Thermo Fisher, RayBiotech)

  • For custom assays, test multiple capture and detection antibody combinations

• Standard curve preparation:

  • Use recombinant human IGFBP6 protein for standard curves

  • Prepare standards in the same matrix as samples to minimize matrix effects

  • Typical standard curve ranges span from pg/ml to ng/ml concentrations

• Sample collection and handling:

  • For cell culture supernatants:

    • Collect after appropriate treatment periods (24h is standard)

    • Centrifuge to remove cellular debris

  • For serum/plasma:

    • Standardize collection methods to minimize pre-analytical variability

    • Use appropriate anticoagulants and process samples within defined timeframes

• Assay protocol optimization:

  • Procedure based on validated protocols includes :

    • Loading standards and samples into antibody-coated wells

    • Binding with biotinylated anti-human antibody

    • Addition of HRP-conjugated streptavidin

    • Developing with TMB substrate solution

    • Measuring optical density at 450 nm

• Validation parameters:

  • Sensitivity: Determine lower limit of detection

  • Precision: Assess intra-assay and inter-assay CV% (aim for <10% and <15% respectively)

  • Recovery: Spike known amounts of recombinant protein into samples

  • Linearity: Test serial dilutions to confirm parallelism with standard curve

  • Specificity: Confirm no cross-reactivity with other IGF family proteins

• Biological sample considerations:

  • Be aware that IGFBP6 levels may differ significantly between:

    • Healthy vs. disease states (e.g., reduced in atherosclerosis )

    • Cancer vs. adjacent normal tissues

    • Different inflammatory conditions

How can I develop robust immunohistochemistry protocols for IGFBP6 detection in different tissue types?

Developing effective immunohistochemistry (IHC) protocols for IGFBP6 detection across tissue types requires systematic optimization:

• Tissue processing and antigen retrieval:

  • Formalin-fixed paraffin-embedded (FFPE) tissues typically require antigen retrieval

  • Test both heat-induced epitope retrieval (HIER) methods:

    • Citrate buffer (pH 6.0)

    • EDTA buffer (pH 9.0)

  • Optimize retrieval times based on tissue type (tumor tissues may require more aggressive retrieval)

• Antibody selection and validation:

  • Choose antibodies validated for IHC applications

  • Test multiple antibody clones/types if available

  • Validate specificity using:

    • Positive control tissues (based on known IGFBP6 expression patterns)

    • Negative controls (omitting primary antibody)

    • Peptide competition controls

• Protocol optimization by tissue type:

  • Breast tissue: Has shown variable IGFBP6 expression correlated with diabetes status

  • Brain tissue: Higher expression in glioblastoma compared to lower-grade gliomas

  • Vascular tissue: Reduced expression in atherosclerotic arteries

  • Liver tissue: Differential expression between HCC and adjacent tissues

• Detection system selection:

  • For low-expressing tissues, employ high-sensitivity detection systems:

    • Polymer-based detection systems

    • Tyramide signal amplification

  • For quantitative analysis, consider chromogenic systems with linear dynamic range

• Counterstaining and visualization:

  • Optimize counterstain intensity to maintain IGFBP6 signal visibility

  • For co-localization studies, consider multiplex IHC approaches

• Quantification approaches:

  • Develop consistent scoring methods:

    • H-score (combines intensity and percentage of positive cells)

    • Digital image analysis for objective quantification

  • Stratify expression levels as demonstrated in breast cancer studies (Table 1 from )

What approaches can resolve contradictory findings about IGFBP6 expression and function in different research models?

Resolving contradictory findings regarding IGFBP6 requires systematic investigation using multiple complementary approaches:

• Comprehensive expression profiling:

  • Apply multiple detection methods concurrently:

    • qRT-PCR for mRNA expression

    • Western blot for protein levels

    • ELISA for secreted protein quantification

  • This multimodal approach can identify discrepancies between transcription and translation

• Context-dependent functional analysis:

  • Investigate IGFBP6 function in multiple cellular contexts:

    • In cystic fibrosis, IGFBP6 shows higher expression in F508del-CFTR cells

    • In glioblastoma, higher IGFBP6 expression indicates worse prognosis

    • In breast cancer, IGFBP6 expression correlates with diabetes status

    • In vascular disease, IGFBP6 has anti-inflammatory effects

• Antibody validation across models:

  • Use multiple antibodies targeting different epitopes

  • Validate each antibody in your specific model system

  • Include appropriate positive and negative controls

• Mechanistic dissection:

  • Employ both gain-of-function and loss-of-function approaches:

    • Neutralizing antibodies to block IGFBP6 function

    • Recombinant IGFBP6 supplementation (0.2-200 ng/ml)

    • siRNA knockdown to reduce endogenous IGFBP6

    • Overexpression systems to increase IGFBP6 levels

• Pathway-specific analysis:

  • Investigate both IGF-dependent and IGF-independent mechanisms:

    • MVP-JNK/NF-κB signaling axis in inflammation

    • MAP kinase pathways in migration

    • IGF-II-dependent proliferation pathways

• Collaborative cross-validation:

  • Establish collaborations between labs studying IGFBP6 in different contexts

  • Develop standardized protocols for cross-laboratory validation

  • Share reagents (especially well-characterized antibodies) to minimize technical variables

By implementing these approaches, researchers can develop a more nuanced understanding of IGFBP6's context-dependent roles and resolve apparent contradictions in the literature.